AstraZeneca today announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients. With SEROQUEL XR(TM) patients can achieve a dose within the recommended range as early as the second day of treatment and the MEB approval also includes relapse prevention in the long-term treatment of schizophrenia. AstraZeneca will proceed with a
AstraZeneca Thailand appoints John Serry as Country President
—
Bangkok: AstraZeneca (Thailand) Ltd., a leading global biopharmaceutical company, today an...
IEAT and AstraZeneca Proactively Conduct Lung Screenings, Visiting GC and SCG Plants for AI-Assisted X-Rays to Drive Early Detection
—
The Industrial Esta...
AstraZeneca Launches "A.Catalyst Network Thailand Hub" A Global Health Innovation Hub - Driving AI-Integrated Healthcare Transformation
—
AstraZeneca (Tha...
IEAT Partners with AstraZeneca, DLPW, and SSO to Launch a Social Initiative "Lung Screening with AI Innovation"
—
IEAT Partners with AstraZeneca, DLPW, an...
HSRI and AstraZeneca Sign an MOU to Advance Clinical Research in MoPH Hospitals Nationwide
—
Strengthening Thailand's Clinical Research Transformation, HS...
กรมสุขภาพจิต ชวนสังคมฟังเสียงสะท้อนผู้ป่วยจิตเภท เปิดใจ ยอมรับ ให้โอกาส และกำลังใจ
—
วันนี้ (24 พ.ค.60) ที่ รพ.ศรีธัญญา นาวาอากาศตรี นายแพทย์บุญเรือง ไตรเ...